FDA requests that the bodyguard material be withdrawn from the market automatically belviq

Today, the FDA issued a drug safety notice, requiring Weicai to automatically withdraw its weight-loss drugs belviq and belviq XR (commonly known as Lorcaserin) FDA analyzed a 12000 person cardiovascular safety clinical trial called camellia-timi 61, and found that although belviq did not increase cardiovascular risk, it would increase the risk of tumor incidence, with an average of one tumor per 470 people per year Major new tumors include pancreatic cancer, colorectal cancer, and lung cancer Today, Weicai stock fell 1% Belviq was originally developed by arena, an American biotechnology company, and was approved for listing in 2012 to lose weight Arena chose Weicai as its sales partner because of its high marketing requirements for weight loss However, the effect of the drug was average and the sales was even worse In 2017, arena sold the potential heavyweight drug once placed high hopes to Weicai for us $23 million Belviq is the only new small molecule weight-loss drug launched in the United States in the past 20 years The other two qysmia and contract are known drug combinations, plus an injection GLP agonist Another new small molecular weight-loss drug is acomplia (commonly known as rimonabant), a CB1 receptor antagonist of Sanofi, which was only listed in Europe and later withdrawn due to central side effects Acomplia has been placed in great hope that in addition to weight loss, it may also be used for other central diseases, and the withdrawal of Sanofi is not a small blow Last year Sanofi announced its withdrawal from the cardiovascular and diabetes fields.